Study of osemitamab, pembrolizumab, and chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as a first treatment for people with advanced or metastatic stomach or gastroesophageal junction cancer. It's looking for patients whose tumors have a specific protein called CLDN18.2, and who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic stomach or gastroesophageal junction cancer that has not been treated before.
- Your tumor must have a protein called CLDN18.2, confirmed by a special test.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are healthy enough to receive chemotherapy and pembrolizumab, and your performance status is 0 or 1.
- You have not had any prior treatment for advanced stomach cancer, and you have not received anti-CLDN18.2 drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy (FLOT) for people with advanced stomach or gastroesophageal junction cancer. It may help if your cancer has not been treated before and you are in reasonably good health.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.